Skip to main content
Image coming soon

FIN6035 Mastering Basel III for Pharma & Life Sciences Risk Leaders

$199.00
Adding to cart… The item has been added

A tailored course, built for your situation

Mastering Basel III for Pharma & Life Sciences Risk Leaders

A structured path to owning capital adequacy and liquidity decisions in regulated financial environments.

$199 one-time
24-hour access provisioning 30-day money-back guarantee Hand-built implementation playbook
12 modules. 12 chapters per module. 144 chapters total.
12 modules, each with 12 chapters (144 chapters total), text-based, plus downloadable templates and a hand-built implementation playbook delivered alongside course access.
Frameworks like Basel III are often interpreted too generically, diluting their strategic value in specialized lending verticals.

The situation this course is for

Generalist interpretations of Basel III can lead to misaligned capital charges for high-variability sectors like life sciences, where asset maturity, R&D risk, and funding models differ sharply from traditional industries. This creates tension between central risk teams and line-of-business leaders, often requiring rework or executive intervention. Without deep fluency in both the framework and the domain, practitioners cede decision authority to broader committees, even on issues they are best positioned to judge.

Who this is for

Senior risk and compliance leaders in financial institutions serving specialized sectors (e.g., life sciences, tech, cleantech) who need to assert ownership over capital adequacy judgments without deferring to centralized teams.

Who this is not for

Junior analysts, auditors focused only on checklist compliance, or generalist risk officers without exposure to Basel III implementation in sector-specific lending environments.

What you walk away with

  • Own internal risk weight calibration for life sciences portfolios without committee escalation
  • Set and justify thresholds for leverage ratio buffers specific to biotech lending cycles
  • Adjust liquidity coverage assumptions based on pipeline development stages
  • Approve capital treatment of contingent liabilities in venture-backed sponsor deals
  • Lead internal validation of Pillar 2 capital add-ons without external facilitation

The 12 modules (with all 144 chapters)

Module 1. Basel III Fundamentals in Sector-Specific Lending
Ground your understanding of Basel III’s three pillars with emphasis on how credit and market risk metrics apply differently in life sciences portfolios compared to traditional corporate lending. Focus on the interaction between long R&D cycles and capital charge design.
12 chapters in this module
  1. Core components of Basel III relevant to non-retail institutions
  2. How Pillar 1 minimums interact with specialized lending risk profiles
  3. Risk-weighted asset calculation for pre-revenue biotech firms
  4. Treatment of intellectual property as collateral under standardized rules
  5. Differences between banking book and trading book treatment for life sciences exposure
  6. Leverage ratio applicability in low-earnings innovation sectors
  7. Liquidity Coverage Ratio assumptions for long-horizon R&D funding
  8. Net Stable Funding Ratio considerations for venture debt structures
  9. Operational risk charge calibration for pharma-focused institutions
  10. Pillar 2 capital add-ons in innovation-intensive portfolios
  11. Role of Internal Capital Adequacy Assessment Process (ICAAP) in life sciences lending
  12. Integration of Basel III principles into business line reporting
Module 2. Capital Adequacy Decision Frameworks
Develop structured methodologies for setting internal capital parameters without escalation. Emphasize defensible, consistent decision logic that aligns with both Basel requirements and business reality.
12 chapters in this module
  1. Establishing internal risk weight bands for clinical trial phases
  2. Setting default probability thresholds for early-stage firms
  3. Calibrating loss given default assumptions based on exit scenarios
  4. Adjusting exposure at default for milestone-based financing
  5. Incorporating sponsor strength into capital treatment
  6. Validating internal models for non-standard collateral
  7. Documenting capital rationale for peer review
  8. Benchmarking against peer-group risk weight practices
  9. Handling currency mismatch in cross-border life sciences lending
  10. Capital treatment of convertible debt structures
  11. Adjusting for sovereign risk in global clinical trials
  12. Escalation criteria for exceptions to standard capital charges
Module 3. Liquidity Risk and Funding Profiles
Tailor liquidity metrics to asset classes with irregular cash flows. Learn how to define stable funding sources and liquidity buffers that reflect real-world pharma financing timelines.
12 chapters in this module
  1. Mapping drug development stages to cash flow predictability
  2. Classifying funding sources by stability for NSFR
  3. Assigning required stable funding factors to life sciences loans
  4. Calculating liquidity coverage for milestone-dependent outflows
  5. Treatment of sponsor commitments in LCR calculations
  6. Adjusting for currency risk in global R&D funding
  7. Incorporating follow-on financing risk into buffer design
  8. Validating internal liquidity assumptions with scenario testing
  9. Capital treatment of off-balance-sheet commitments
  10. Handling multi-currency liquidity needs in international trials
  11. Defining eligible HQLA for pharma-focused portfolios
  12. Documentation standards for liquidity policy exceptions
Module 4. Internal Risk Weight Assignment
Build a defensible framework for assigning internal risk weights that reflect the unique risk drivers in life sciences lending, including clinical success probability and IP strength.
12 chapters in this module
  1. Clinical phase progression as a risk driver
  2. Patent strength and expiration risk scoring
  3. Sponsor funding runway analysis
  4. Regulatory pathway uncertainty scoring
  5. Market size and reimbursement risk integration
  6. Competitive landscape pressure factors
  7. Management team track record weighting
  8. Manufacturing scalability risk assessment
  9. IP litigation risk indicators
  10. Geopolitical risks in clinical trial locations
  11. Data exclusivity and regulatory cliff risk
  12. Integration of external rating input into internal weights
Module 5. Leverage Ratio Threshold Design
Define appropriate leverage ratio thresholds that balance regulatory compliance with business growth objectives in capital-intensive sectors.
12 chapters in this module
  1. Baseline leverage ratio for pharma-focused lending units
  2. Adjusting for portfolio concentration risk
  3. Incorporating stage-specific volatility factors
  4. Treatment of unsecured vs. secured venture debt
  5. Impact of macroeconomic shifts on leverage tolerance
  6. Stress-testing leverage assumptions across cycles
  7. Setting internal triggers for leverage review
  8. Documentation required for threshold adjustments
  9. Benchmarking against peer institutions in specialty finance
  10. Capital treatment of non-controlling investments
  11. Handling cross-portfolio aggregation limits
  12. Escalation paths for threshold breaches
Module 6. Pillar 2 Capital Add-Ons
Design and implement institution-specific capital add-ons under Pillar 2 that reflect concentrated exposures and strategic risk in life sciences lending.
12 chapters in this module
  1. Identifying concentrations requiring capital add-ons
  2. Measuring exposure to clinical trial stage clustering
  3. Assessing sponsor dependency risk
  4. Incorporating reputational risk from trial failures
  5. Capital treatment for multi-jurisdictional compliance
  6. Stress-testing models for binary event risk
  7. Defining governance for add-on calibration
  8. Documenting rationale for internal capital charges
  9. Review cycles for Pillar 2 adjustments
  10. Treatment of emerging technology risks (e.g., gene editing)
  11. Integration with ICAAP reporting
  12. Escalation process for proposed add-on changes
Module 7. ICAAP Leadership and Ownership
Lead your unit’s Internal Capital Adequacy Assessment Process with confidence, ensuring alignment with both regulatory expectations and business strategy.
12 chapters in this module
  1. Defining ownership of ICAAP components within your function
  2. Scenarios specific to life sciences loan portfolio stress
  3. Incorporating R&D failure probability into stress tests
  4. Capital planning for pipeline-dependent borrowers
  5. Liquidity stress under delayed FDA approvals
  6. Funding risk under investor pullback scenarios
  7. Reputation risk impact on capital planning
  8. Documentation standards for ICAAP submissions
  9. Engagement with central risk teams on assumptions
  10. Scenario validation with historical biotech downturns
  11. Internal review cycles for ICAAP updates
  12. Presenting ICAAP outcomes to leadership
Module 8. Regulatory Interaction and Transparency
Prepare for regulator engagements by building clear, evidence-backed narratives around capital and liquidity decisions in specialized portfolios.
12 chapters in this module
  1. Responding to questions on internal risk weight logic
  2. Justifying deviations from standardized approaches
  3. Presenting stress test assumptions to examiners
  4. Documenting model validation processes
  5. Handling requests for portfolio-level capital analysis
  6. Transparency in Pillar 2 capital determination
  7. Evidence standards for internal methodologies
  8. Preparing for on-site Basel-related reviews
  9. Responding to supervisory feedback on capital adequacy
  10. Maintaining audit trails for capital decisions
  11. Version control for capital models and inputs
  12. Coordination with compliance teams on regulatory queries
Module 9. Cross-Functional Capital Governance
Establish clear decision rights and reporting structures for capital-related choices across risk, finance, and business units.
12 chapters in this module
  1. Defining decision ownership for capital parameters
  2. Escalation paths for cross-portfolio conflicts
  3. Role clarity between central and line risk units
  4. Finance team integration into capital planning
  5. Business unit input into stress scenario design
  6. Documentation standards for capital governance meetings
  7. Meeting frequency and agenda for capital reviews
  8. Approval workflows for capital assumption changes
  9. Track records for past capital decisions
  10. Integration with budgeting and forecasting
  11. Handling discrepancies in capital interpretation
  12. Maintaining capital governance policy versions
Module 10. Model Validation and Audit Readiness
Ensure internal models for capital adequacy are robust, transparent, and defensible during audits and regulatory reviews.
12 chapters in this module
  1. Internal validation of risk weight models
  2. Back-testing performance of capital assumptions
  3. Documentation required for model audit trails
  4. Handling third-party model reviews
  5. Version control for capital calculation tools
  6. Data quality requirements for inputs
  7. Governance of model changes and updates
  8. Stress-testing validation procedures
  9. Peer benchmarking for model reasonableness
  10. Response process for model criticism
  11. Updating models based on new data
  12. Training teams on model assumptions and limitations
Module 11. Capital Communication to Leadership
Frame capital adequacy topics for executive audiences using clear, actionable narratives grounded in business context.
12 chapters in this module
  1. Translating risk weights into business impact
  2. Communicating leverage ratio implications to executives
  3. Visualizing liquidity coverage scenarios
  4. Presenting Pillar 2 add-on rationale
  5. Explaining capital buffer decisions under uncertainty
  6. Narratives for capital allocation trade-offs
  7. Dashboard design for capital metrics
  8. Handling executive challenges to capital assumptions
  9. Aligning capital messaging with strategic goals
  10. Preparing leadership for regulatory dialogue
  11. Summarizing ICAAP outcomes for non-specialists
  12. Timing of capital-related updates to leadership
Module 12. Sustaining Capital Fluency Across Leadership Changes
Build institutional memory and structured handoffs so capital decision frameworks endure beyond individual contributors.
12 chapters in this module
  1. Documenting capital decision rationale systematically
  2. Building playbook for new hires in risk roles
  3. Standardizing onboarding for capital frameworks
  4. Maintaining institutional knowledge bases
  5. Succession planning for capital ownership
  6. Versioning capital policies and updates
  7. Creating audit-ready archives of past decisions
  8. Training programs for emerging leaders
  9. Ensuring continuity during restructuring
  10. Integrating capital fluency into performance goals
  11. Feedback loops from capital outcomes to training
  12. Evolving frameworks based on regulatory changes

How this maps to your situation

  • Capital adequacy in specialized lending environments
  • Liquidity risk in innovation-driven portfolios
  • Internal risk weight calibration for biotech assets
  • Leadership in ICAAP and Pillar 2 processes

Before vs. after

Before
Capital adequacy decisions are often deferred to centralized risk teams, even when line leaders have the domain expertise.
After
You own key capital parameters , risk weights, buffers, and thresholds , with defensible, documented reasoning that stands up to scrutiny.

What's included with your purchase

  • 12 modules with 12 chapters each (144 chapters)
  • Downloadable templates and worked examples for every module
  • Hand-built implementation playbook delivered alongside course access
  • 30-day money-back guarantee

Delivery and format

  • Course and learning environment access provisioned within 24 hours of purchase
  • Hand-built implementation playbook delivered alongside course access

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.

Time investment: Approximately 90 minutes per module, designed for completion over a 12-week period with real-world application between modules.

If nothing changes
Without structured fluency in Basel III application to life sciences, decision authority remains centralized, limiting your strategic influence and slowing portfolio-specific risk optimization.

How this compares to the alternatives

Public Basel III courses focus on generic banking applications. This course is tailored to practitioners in financial institutions serving high-variability sectors like life sciences, where capital modeling must reflect innovation risk, long development cycles, and milestone-driven financing.

Frequently asked

Is this course relevant if I don’t work in traditional banking?
Yes. It’s designed specifically for risk leaders in financial institutions that serve non-traditional, innovation-driven sectors like life sciences and tech.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Does this cover Basel IV changes as well?
The course focuses on Basel III implementation with forward-looking insights into upcoming revisions, ensuring your fluency evolves with regulatory expectations.
$199 one-time. Approximately 90 minutes per module, designed for completion over a 12-week period with real-world application between modules..

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.

30-day money-back guarantee· 144 chapters· Hand-built playbook included· Account access within 24 hours
!